A cell-penetrating MARCKS mimetic selectively triggers cytolytic death in glioblastoma

• Published in: Oncogene Vol. 39; no. 46; pp. 6961 - 6974
• Main Authors: Eustace, Nicholas J, Anderson, Joshua C, Warram, Jason M, Widden, Hayley N, Pedersen, Rune T, Alrefai, Hasan, Patel, Zeel, Hicks, Patricia H, Placzek, William J, Gillespie, G Yancey, Hjelmeland, Anita B, Willey, Christopher D
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 12.11.2020
• Subjects: Alanine; Animals; Apoptosis; Apoptosis - drug effects; Astrocytes; Blood-Brain Barrier - cytology; Blood-Brain Barrier - metabolism; Brain cancer; Brain Neoplasms - drug therapy; Brain Neoplasms - pathology; Calcium (intracellular); Care and treatment; Caspase; Caspases - metabolism; Cell death; Cell Line, Tumor; Cell Membrane Permeability; Cellular proteins; Chemotherapy; Cytotoxicity; Development and progression; Drug Resistance, Neoplasm - drug effects; Genetic aspects; Glioblastoma; Glioblastoma - drug therapy; Glioblastoma - pathology; Glioblastoma multiforme; Health aspects; Humans; Malignancy; MARCKS protein; Mice; Myristoylated Alanine-Rich C Kinase Substrate - genetics; Peptide Fragments - genetics; Peptide Fragments - pharmacology; Peptide Fragments - therapeutic use; Peptides; Phospholipids; Protein Domains - genetics; Signal Transduction - drug effects; Stem cells; Surgery; Temozolomide; Tissue Distribution; Tumors; Xenograft Model Antitumor Assays; Xenografts; United States

Glioblastoma (GBM) is an aggressive malignancy with limited effectiveness of standard of care therapies including surgery, radiation, and temozolomide chemotherapy necessitating novel therapeutics. Unfortunately, GBMs also harbor several signaling alterations that protect them from traditional thera...